Suppr超能文献

[阿糖胞苷(ACNU)联合放疗及增敏剂治疗恶性胶质瘤的试验]

[A trial of ACNU and radiation therapy with sensitizing agents for malignant gliomas].

作者信息

Kawano H, Hayashi M, Satoh K, Ishii H, Nakatsugawa S, Ishii Y

机构信息

Department of Neurosurgery, Fukui Medical School, Matsuoka, Japan.

出版信息

No To Shinkei. 1989 Nov;41(11):1071-5.

PMID:2620008
Abstract

Twelve cases of malignant gliomas (anaplastic astrocytoma 4, glioblastoma 8, recurrent 3, primary 9) were treated with ACNU and radiation with sensitizing agents after the surgical removal of the tumor. BUdR, Vidarabine (Ara-A), Aciclovir (ACV) were applied for sensitizing agents. BUdR was administrated intraarterially prior to radiation (380 rad, two times a week), and Ara-A and ACV intravenously during and after the radiation. Total dosage of the radiation was 50-60 Grey for each case. All recurrent and eight primary patients died. The mean survival time of the recurrent patients was 17.7 months, while that of the primary patients was 13.4 months. One of the primary patient was glioblastoma and is still surviving more than 24 months by now. The complete response (CR) rate of the primary tumor patients observed by computerized tomography (CT) scan was 5/9. We can expect the availability of this trial for malignant gliomas because of high CR rate in primary tumor cases.

摘要

12例恶性胶质瘤患者(间变性星形细胞瘤4例,胶质母细胞瘤8例,复发性3例,原发性9例)在肿瘤手术切除后接受了阿糖胞苷(ACNU)治疗,并联合放疗增敏剂进行放疗。使用溴脱氧尿苷(BUdR)、阿糖腺苷(Ara - A)、阿昔洛韦(ACV)作为增敏剂。在放疗前(380拉德,每周两次)经动脉给予BUdR,在放疗期间及放疗后经静脉给予Ara - A和ACV。每例患者的放疗总剂量为50 - 60戈瑞。所有复发性患者及8例原发性患者均死亡。复发性患者的平均生存时间为17.7个月,原发性患者的平均生存时间为13.4个月。1例原发性胶质母细胞瘤患者至今仍存活超过24个月。通过计算机断层扫描(CT)观察,原发性肿瘤患者的完全缓解(CR)率为5/9。由于原发性肿瘤病例的CR率较高,我们可以期待该试验对恶性胶质瘤的有效性。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验